Cargando…
Inhibition of terminal complement activation in severe Shiga toxin-associated HUS – perfect example for a fast track from bench to bedside
Autores principales: | Orth-Höller, Dorothea, Riedl, Magdalena, Würzner, Reinhard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
WILEY-VCH Verlag
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3377111/ https://www.ncbi.nlm.nih.gov/pubmed/21954211 http://dx.doi.org/10.1002/emmm.201100169 |
Ejemplares similares
-
Method for the Detection of the Cleaved Form of Shiga Toxin 2a Added to Normal Human Serum
por: Rocchetti, Lucrezia, et al.
Publicado: (2021) -
Shiga Toxin 2a Binds to Complement Components C3b and C5 and Upregulates Their Gene Expression in Human Cell Lines
por: Kellnerová, Sára, et al.
Publicado: (2020) -
The Shiga Toxin Receptor Globotriaosylceramide as Therapeutic Target in Shiga Toxin E. coli Mediated HUS
por: Feitz, Wouter J. C., et al.
Publicado: (2021) -
Treatment of Shiga-Toxin Hus with Severe Neurologic Features with Eculizumab
por: Umscheid, Jacob H., et al.
Publicado: (2021) -
Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS)
por: Scheiring, Johanna, et al.
Publicado: (2008)